[ad_1]
Moderna said on Tuesday that its COVID-19 vaccine can provide strong protection for children under the age of 12. This step may put the vaccination on the right track and become the second option for this age group in the United States.
While the global vaccine supply is still tight, many parts of the world are working hard to vaccinate adults in order to end the pandemic. But earlier this month, the United States and Canada approved another vaccine-vaccines produced by Pfizer and BioNTech-starting at the age of 12.
Moderna CEO Stéphane Bancel said in a statement: “We will submit these results to the US FDA and global regulatory agencies in early June and request authorization.” “We will continue to work to help end the COVID-19 pandemic.”
The company studied more than 3,700 children between the ages of 12 and 17. Preliminary findings indicate that the vaccine triggers the same signs of immune protection in children as adults, and produces similar temporary side effects, such as arm soreness, headaches and fatigue.
There was no diagnosis of COVID-19 among children who received two doses of Moderna vaccine, compared to four cases among children who received fake vaccines. The company also stated in a press release that 93% of the vaccine was effective two weeks after the first injection.
Children account for 14% of U.S. coronavirus cases
According to statistics from the American Academy of Pediatrics, although children are less likely to be seriously ill from COVID-19 than adults, they account for about 14% of coronavirus cases in the United States, with 316 deaths in the United States alone. .
Health Canada’s case summary shows that Canadians under the age of 19 accounted for 18.8% of Canadians and accounted for 1.7% of the total number of COVID-19 hospitalizations. Compared with the two previous waves of coronavirus, among people 19 and under, the number of cases rose sharply from March to mid-April, and then stabilized. Health Canada reported that 11 of this population died during the pandemic.
Watch | 14-year-old and 11-year-old Canadian girls share their vaccine experience:
Andrew Chang talked to two young Canadians who had recently received vaccinations. He talked about their situation at the time, the challenges of the past year and what they most look forward to. 6:13
Since the United States has a large supply of vaccines, in the few days after the FDA opened it to them, teenagers flocked to receive Pfizer’s vaccination. This is a driving force for vaccinating as many children as possible before the next school year. Part.
Both Pfizer and Moderna have begun testing on younger children (from 11 years old to 6 months old). This test is more complicated: teens receive the same dose as adults, but researchers are testing smaller doses on younger children. Experts hope to see some results in the fall.
[ad_2]
Source link
